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IMPORTANCE The clinical benefit of adding amacrolide to a β-lactam for empirical treatment
of moderately severe community-acquired pneumonia remains controversial.
OBJECTIVE To test noninferiority of a β-lactam alone compared with a β-lactam and
macrolide combination in moderately severe community-acquired pneumonia.
DESIGN, SETTING, AND PARTICIPANTS Open-label, multicenter, noninferiority, randomized trial
conducted from January 13, 2009, through January 31, 2013, in 580 immunocompetent adult
patients hospitalized in 6 acute care hospitals in Switzerland for moderately severe
community-acquired pneumonia. Follow-up extended to 90 days. Outcome assessors were
masked to treatment allocation.
INTERVENTIONS Patients were treated with a β-lactam and amacrolide (combination arm) or
with a β-lactam alone (monotherapy arm). Legionella pneumophila infection was
systematically searched and treated by addition of a macrolide to themonotherapy arm.
MAIN OUTCOMES ANDMEASURES Proportion of patients not reaching clinical stability (heart
rate <100/min, systolic blood pressure >90mmHg, temperature <38.0°C, respiratory rate
<24/min, and oxygen saturation >90% on room air) at day 7.
RESULTS After 7 days of treatment, 120 of 291 patients (41.2%) in themonotherapy arm vs 97
of 289 (33.6%) in the combination arm had not reached clinical stability (7.6% difference,
P = .07). The upper limit of the 1-sided 90%CI was 13.0%, exceeding the predefined
noninferiority boundary of 8%. Patients infected with atypical pathogens (hazard ratio [HR],
0.33; 95% CI, 0.13-0.85) or with Pneumonia Severity Index (PSI) category IV pneumonia (HR,
0.81; 95% CI, 0.59-1.10) were less likely to reach clinical stability with monotherapy, whereas
patients not infected with atypical pathogens (HR, 0.99; 95% CI, 0.80-1.22) or with PSI
category I to III pneumonia (HR, 1.06; 95% CI, 0.82-1.36) had equivalent outcomes in the 2
arms. There were more 30-day readmissions in themonotherapy arm (7.9% vs 3.1%, P = .01).
Mortality, intensive care unit admission, complications, length of stay, and recurrence of
pneumonia within 90 days did not differ between the 2 arms.
CONCLUSIONS AND RELEVANCE We did not find noninferiority of β-lactammonotherapy in
patients hospitalized for moderately severe community-acquired pneumonia. Patients
infected with atypical pathogens or with PSI category IV pneumonia had delayed clinical
stability with monotherapy.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00818610
JAMA Intern Med. 2014;174(12):1894-1901. doi:10.1001/jamainternmed.2014.4887
Published online October 6, 2014.
Invited Commentary
page 1901
Supplemental content at
jamainternalmedicine.com
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author:Nicolas
Garin, MD, Division of Internal
Medicine, Hôpital Riviera-Chablais,
Route deMorgins 54, 1870Monthey,
Switzerland (nicolas.garin
@hopitalduchablais.ch).
Research
Original Investigation
1894 jamainternalmedicine.com
Downloaded From:  by a UNIVERSITE DE LAUSANNE User  on 10/13/2017
Copyright 2014 American Medical Association. All rights reserved.
C ommunity-acquiredpneumoniaaccounts forahighbur-den of deaths, hospitalizations, andhealth care costs.1Optimal coverage of Streptococcus pneumoniae, gener-
ally with a β-lactam, is advocated for hospitalized patients.
However, the need to cover atypical pathogens (eg, Legion-
ella species, Mycoplasma pneumoniae, and Chlamydia pneu-
moniae) byaddingamacrolide to theβ-lactamregimenorwith
fluoroquinolone monotherapy is debated. A meta-analysis2
found better outcomes in patients treated with the combina-
tion of amacrolidewith a β-lactamcomparedwith a β-lactam
alone. However, confounding can be a problem because pa-
tients treated with combination therapy are younger and
healthier.3,4 A meta-analysis5 of randomized trials that com-
pared antibiotic regimenswith andwithout coverageof atypi-
cal pathogens did not find superiority in either arm. How-
ever, no trial that compared a β-lactam alone with a
combination of a β-lactam and a macrolide was identified.
Moreover, clinical successwasassessedafter completionof the
antibiotic treatment,whichmight preclude the identification
of adifference in the speedof resolutionof thepneumoniabe-
tween arms.
Because of this uncertainty, international medical soci-
eties differ in their recommendations.NorthAmerican guide-
linesrecommendempiricalcoverageofatypicalpathogenswith
arespiratory fluoroquinoloneorwiththecombinationofamac-
rolide and a β-lactam for all hospitalized patients.6 European
guidelines recommendcombination therapyonly formore se-
verely ill patients.7
The addition of a macrolide has potential drawbacks.
Macrolide use is associated with possible adverse cardiovas-
cular events8 and cardiovascular death.9,10 This association
is relevant because pneumonia affects predominantly older
people, who are at increased risk of heart disease, and pneu-
monia itself is a trigger for adverse cardiac events.11 Macro-
lides may also promote resistance of S pneumoniae against
multiple antibiotic classes.12,13 On the other hand, macro-
lides cover atypical pathogens andmight affect favorably the
host inflammatory response through nonantibiotic effects.14
Consequently, potential advantages of combination therapy
should be balanced with a potential increased risk of adverse
cardiac events and increased selection of resistant patho-
gens. We aimed to evaluate whether initial empirical treat-
ment with β-lactam monotherapy was noninferior to the
combination of a β-lactam and a macrolide in adult patients
hospitalized for moderately severe community-acquired
pneumonia.
Methods
Design and Patients
Theethics committeesof all participatinghospitals andSwiss-
medic, the Swiss regulatory agency for therapeutic products,
approved the studyprotocol. All patients providedwritten in-
formedconsent.TheBICAPDSMB,an independentdata safety
monitoring board, was informed about the number of severe
events inboth treatmentarmsandcould stop the trial if judged
necessary.
This open-label, noninferiority, randomized trialwas con-
ducted in 6 acute care hospitals in Switzerland. We screened
consecutivepatientswhopresented to the emergencydepart-
ment with suspected community-acquired pneumonia and
who needed hospitalization. Inclusion criteria were an age of
18 years or older, presence of at least 2 clinical findings sug-
gestiveofpneumonia, andpresenceofanewinfiltrateonchest
radiograph.Main exclusion criteriawere severe immunosup-
pression, recenthospitalization (<14days), residency inanurs-
inghome, severe pneumonia as definedby the InfectiousDis-
easesSocietyofAmerica/AmericanThoracicSociety2007 rule6
or Pneumonia Severity Index (PSI) category V,15 and adminis-
tration of any antibiotic for more than 24 hours before inclu-
sion (eMethods in the Supplement).
Randomization
Randomizationwascomputer generatedandstratifiedbycen-
ter,with a 1:1 ratio, in randomly alternating blocks of 6, 8, and
10.After informedconsent,patientswereallocated to the treat-
ment arms by means of consecutive, numbered, sealed, and
opaque envelopes.
Intervention
Patientswere randomized to initial treatmentwith a β-lactam
alone (monotherapyarm)or a β-lactamandamacrolide (com-
bination arm). Theβ-lactamcouldbe cefuroxime (1.5 g 3 times
a day intravenously) or amoxicillin and clavulanic acid (1.2 g
intravenously 4 times a day). Themacrolidewas clarithromy-
cin, 500 mg twice a day intravenously or orally (eMethods in
theSupplement).Urine sampleswere systematically tested for
the presence of Legionella pneumophila antigen, and a mac-
rolide was added in the monotherapy arm in case of a posi-
tive test result. A change in the assigned treatment was only
allowed in the case of clinical deterioration that necessitated
admission to the intensive care unit, lack of resolution of fe-
ver after 72 hours, or isolation of a resistant pathogen.
Outcomes and Follow-up
The primary outcomewas the proportion of patientswho did
not reach clinical stability at day 7, defined as a heart rate less
than 100/min, systolic bloodpressureofmore than90mmHg,
tympanic temperature less than 38.0°C, respiratory rate less
than24/min, andoxygensaturationbypulseoximetryofmore
than90%on roomair. Vital signsweremeasuredat least twice
aday.Time to clinical stabilitywasdefinedas timeelapsedbe-
tween the first antibiotic dose and the first time all 5 criteria
were reachedandmaintained foraminimumof24hours.Time
to clinical stability was determined separately after comple-
tionof the trial by investigators (N.G. andS.C.)masked to treat-
ment allocation. Discrepancies were resolved by consensus.
Secondaryoutcomeswere30-and90-daymortality, trans-
fer to the intensive care unit, length of stay, readmission, re-
currence of pneumonia, subsequent introduction of any new
antibiotic, andcomplicatedpleural effusion that requiredchest
tube insertionor thoracic surgery.Patientswereassessedclini-
cally for 30 days or until hospital discharge. All patients were
contacted by telephone at 30 and 90 days. The general prac-
titioner or thehospitalwas contacted to verifywhether a sub-
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sequent pneumonia confirmed by chest radiography had oc-
curred. Two investigators (N.G. andS.C.) examined separately
themedical recordsofpatients readmittedanddetermined the
causeof readmission.Adverse events, including suspected al-
lergyor toxiceffectsattributedto theantibiotic treatment,were
identified on standard forms.
Diagnostic Tests and Diagnostic Criteria
Twopairs of blood cultureswere obtained before administra-
tion of antibiotics. A urine samplewas collected for detection
of the L pneumophila antigen. Detection of the S pneumoniae
antigen in theurinewas left to thediscretionof thehealth care
professionals. Sputumandpleural fluidwere sampledandcul-
tured according to published recommendations.7 A pharyn-
geal swab was obtained on the first day of the study and pro-
cessed for detection of C pneumoniae and M pneumoniae by
polymerase chain reaction. Results of the swab test were not
madeavailable to thehealth careprofessionals.Diagnostic cri-
teria are available in the eMethods in the Supplement.
Statistical Analysis
Because there is no randomized clinical trial, to our knowl-
edge, thatcomparesantibiotic treatmentwithaplacebo incom-
munity-acquiredpneumonia,we couldnot compute thenon-
inferioritymargin as apercentageof theeffect of the reference
treatmentoverplacebo, as generally recommended.Wechose
the noninferiority margin in reference to unofficial US Food
and Drug Administration recommendations for anti-
infectious trials that assessed clinical success of a new treat-
ment,which recommendanoninferioritymargin of 10%.16 To
beconservative,wecomputed thesamplesizewithan8%non-
inferiority margin.
We assumed a proportion of patients not having reached
clinical stability at day 7 of 16% in the combination arm.17,18
We needed 280 patients per arm to have 90% power with a
1-sided α of .10.19 Continuous variables are reported as mean
(SD)ormedian (interquartile range [IQR]) andcategorical vari-
ablesasnumber (percentage).Between-groupdifferenceswere
assessed using the t test, Wilcoxon rank sum test, χ2 test, or
Fisher exact test, as appropriate.
The proportions (SEs) of unstable patients at 7 days were
measuredby theKaplan-Meiermethod.Unstablepatientswho
were discharged were censored, and patients who died were
considered unstable. We computed the SE on the difference
between proportions (seΔ), calculated as:
√sem2 + se2b),
where the subscriptsm and b identify the monotherapy and
combination therapy arms, and used this value to obtain the
upper limit of a 90% CI, which was used to test the noninfe-
riority hypothesis, and a 2-sided 95%CI, whichwas provided
for descriptive purposes. We also tested the null hypothesis
of no difference between the proportions using a χ2 test and
reported the corresponding P value.
Secondaryanalyseswereprespecified.Toperformaglobal
comparisonof the2 studyarms,weobtainedKaplan-Meier es-
timates for the time to clinical stability along with a log-rank
test and computed a hazard ratio (HR) from a Cox propor-
tional hazards model. We performed this analysis again with
an adjustment for patient age and the PSI score. Three pre-
specifiedsubgroupanalyseswereconducted, stratifyingonthe
category of the pathogen identified (atypical or nonatypical,
defined as all patients without identification of an atypical
pathogen), patient age (<65 or ≥65 years), andPSI (category IV
vs I to III).We also performed an additional post hoc analysis,
stratifying by the CURB-65 (confusion, urea, respiratory rate,
bloodpressure, age≥65years) score (≥2vs<2). Stratawerecom-
pared inaCoxproportionalhazardsmodel that includedas co-
variates the treatment, stratification variable, and interac-
tion between the 2 covariates.
Because theKaplan-Meier survival curves crossduring the
first week, it follows that the hazards are not strictly propor-
tional.However,webelieve that thenonproportionality is not
major and that the HR captures a scientifically relevant sta-
tistic (ie, the mean HR during the first 7 days). Use of a more
complex model (eg, a time-dependent treatment effect with
HR[t] a linear function of ln[t] or a stepwise Cox proportional
hazards model with a different HR for days 0-3 and days 4-7)
would improve fit, but these analyses would not test the pre-
specified research question, “Is there a general disadvantage
(in terms of time to stability during the first week) to using
monotherapy in this indication?”
Significance was defined as a 2-tailed P < .05. All analy-
ses were performed in the intent-to-treat populations using
SPSS statistical software, version 18.0 (SPSS Inc).
Results
From January 13, 2009, through January 31, 2013, we in-
cluded602patients in the study.Twenty-twopatientswereex-
cluded after randomization (Figure 1), leaving a total of 580
patients (291 in the monotherapy arm and 289 in the combi-
nation arm). Patients had amedian age of 76 years (range, 21-
101 years), and 351 (60.5%) had 1 or more comorbidities (me-
dian, 1.0; IQR, 0-2). The mean PSI score was 84 (Table 1).
Microbiologic Analysis Results
No imbalance was found between the study arms in the bac-
teriologic investigations (eTable 1 in theSupplement).Apatho-
gen was identified in 180 patients (31.0%), and 48 (8.3%) had
bacteremia. Streptococcus pneumoniae, the most common
pathogen, was isolated in 43 patients (14.8%) in the mono-
therapy arm and 45 (15.6%) in the combination arm. Legion-
ella pneumophila was identified in 12 patients (4.1%) in the
monotherapy arm and 4 (1.4%) in the combination arm. The
resultofpolymerasechain reaction forMpneumoniaewasposi-
tive in 6 patients (2.1%) in the monotherapy arm and 9 (3.1%)
in the combination arm (eTable 1 in the Supplement).
Treatment
Twenty-six patients (4.5%) had been treatedwith oral antibi-
otics before inclusion in the trial. Patients were treated with
antibiotics for amedianof 10.0days (IQR, 8.0-12.0days) in the
monotherapy armvs 10.0days (IQR, 7.0-11.0days) in the com-
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bination arm (P = .41). The β-lactam agent used was amoxi-
cillin–clavulanic acid in 224 patients (77.0%) in the mono-
therapy arm and 215 patients (74.4%) in the combination arm
(P = .48). The remaining 141 patients were treated with cefu-
roxime.
Initial antibiotic treatment was changed in 39 patients
(13.4%) in themonotherapy arm and 46 (15.9%) in the combi-
nationarm(P = .39).The reasons for changeare listed ineTable
2 in theSupplement.Median timebeforeadministrationof cla-
rithromycin was 47 hours in the patients with L pneumophila
infection in the monotherapy arm.
Primary Outcome
After 7 days of treatment, 120 patients (41.2%) in the mono-
therapy armhad not reached clinical stability comparedwith
97 (33.6%) in the combination arm (P = .07). The absolute dif-
ference was 7.6%, with an upper limit of the 90% CI of 13.0%
anda2-sided95%CIof−0.8%to16.0%(Table2).Because13.0%
is above the predefined boundary of 8%, noninferiority of
monotherapycouldnotbedemonstrated. In thesurvivalanaly-
sis, no significant difference was found between the treat-
ment arms (HRof reaching stability, 0.93; 95%CI, 0.76-1.13), a
result thatdidnot changesignificantlyafter adjustment for age
andPSI category (Table 3). Onvisual inspectionof theKaplan-
Meier curves (Figure 2), the difference in the proportions of
unstable patients peakedonday 7 andpersisteduntil 30days,
although it was globally nonsignificant (P = .44 by the log-
rank test). Median time to clinical stability was 5.0 days (IQR,
3.8-6.2 days) in the monotherapy arm and 4.5 days (IQR, 3.9-
5.1 days) in the combination arm.Mean time to clinical stabil-
ity and stabilization of the independent vital parameters is
given in eTable 3 in the Supplement.
Subgroup Analysis
In the subgroup analysis, the effect of the treatment arm dif-
fered significantly for patientswith identification of an atypi-
cal pathogen (HR of reaching stability, 0.33; 95% CI, 0.13-
0.85) and those without (HR, 0.99; 95% CI, 0.80-1.22).
Combination therapy was significantly superior for patients
with atypical pathogens (Table 3). There was a trend toward
better outcome of the combination therapy for patients with
more severe pneumonia (Table 3 and eFigure 1 in the Supple-
ment). PatientswithPSI category I to III pneumoniahadanHR
of reaching stability of 1.06 (95% CI, 0.82-1.36) with mono-
therapy.ThecorrespondingHRwas0.81 (95%CI, 0.59-1.10) for
patients with PSI category IV pneumonia (P = .18 for trend).
When stratifying on the basis of the CURB-65 score, theHRof
Figure 1. Randomization of Patients in the Study
602 Patients randomized
291 Completed 30-day follow-up 289 Completed 30-day follow-up
291 Included in analysis for the primary end point 289 Included in analysis for the primary end point
300 Allocated to monotherapy arm
291 Treated with initial monotherapy
9 Excluded after randomization
6 Had another diagnosis or no pulmonary infiltrate
2 Had exclusion criteria
1 Withdrew his consent
302 Allocated to combination therapy arm
289 Treated with initial combination therapy
13 Excluded after randomization
7 Had another diagnosis or no pulmonary
infiltrate
5 Had exclusion criteria
1 Withdrew his consent
Table 1. Patient Characteristics at Baselinea
Characteristic
Monotherapy
(n = 291)
Combination
Therapy
(n = 289)
Age, median (IQR), y 76 (63-84) 76 (64-83)
Male sex 162 (55.7) 171 (59.2)
Comorbidities, median (IQR) 1 (0-2) 1 (0-2)
Chronic heart failure 64 (22.0) 52 (18.0)
Chronic obstructive pulmonary disease 61 (21.0) 61 (21.1)
Diabetes mellitus 44 (15.1) 52 (18.0)
Chronic renal failure 47 (16.2) 41 (14.2)
PSI score, mean (SD) 84.5 (25.8) 84.2 (24.1)
PSI category
I 31 (10.7) 23 (8.0)
II 50 (17.2) 55 (19.0)
III 83 (28.5) 98 (33.9)
IV 127 (43.6) 113 (39.1)
CURB-65 score ≥2 155 (53.3) 156 (54.0)
Heart rate, mean (SD), /min 100 (21) 97 (18)
Respiratory rate, mean (SD), /min 24.5 (6.2) 23.6 (5.8)
Temperature, mean (SD), °C 37.9 (1.0) 37.9 (1.0)
Hypoxemiab 206 (70.8) 219 (75.8)
Pleural effusion 46 (15.8) 51 (17.6)
White blood cells, mean (SD), /μL 13 400 (6300) 13 600 (6500)
Abbreviations: CURB-65, confusion, urea, respiratory rate, blood pressure, age
of 65 years or older; IQR, interquartile range; PSI, Pneumonia Severity Index.
SI conversion factor: To convert white blood cells to ×109/L, multiply by 0.001.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
bHypoxemia was defined as arterial oxygen saturation less than 92%with room
air or the need for supplemental oxygen.
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reaching stability with monotherapy was 1.13 (95% CI, 0.85-
1.50) for patientswith CURB-65 scores of 0 or 1 and 0.80 (95%
CI, 0.61-1.06) for patients with CURB-65 scores of 2 or higher
(P = .09 for interaction).No interactionwas foundbetweenage
and treatment arm (Table 3).
Inaposthocanalysis thatexcludedallpatientswithproven
infection by an atypical pathogen, the proportion of patients
not having reached clinical stability at day 7was 39.9% in the
monotherapy arm and 34.1% in the combination arm (abso-
lute difference, 5.8%; 95% CI, −2.7% to 14.3%; P = .15). Mean
PSI scoreswere86.4 inpatientswithand84.2 inpatientswith-
out a proven atypical pathogen infection (P = .64 by analysis
of variance).
Secondary Outcomes
No differencewas found between the 2 arms inmost second-
ary outcomes (Table 2). However, at 30 days after discharge,
more patients in the monotherapy arm had been readmitted
(7.9% vs 3.1% in the combination arm, P = .01). Of the 23 pa-
tients in the monotherapy arm who had been readmitted, 7
(30.4%)had anewepisode of pneumonia vs 0 of 9 in the com-
bination arm (P = .06).Other causes of readmissionorpropor-
tionofpatients treated for anewepisodeofpneumonia (in the
hospital or as outpatients) did not differ between the treat-
ment arms (Table 2 and eTable 4 in the Supplement).
Therewasa trend towardmore severeevents in themono-
therapyarm inpatients infectedwith anatypical pathogen, in-
cluding 3 intensive careunit admissions (all 3 patientswere in-
fectedwith L pneumophila) vs none (P = .12), respectively and
2deaths (bothpatientswere infectedwithMpneumoniae) at 30
daysvsnone(P = .21), respectively (eTable5 intheSupplement).
Safety
Adverse events attributed to the antibiotic treatmentwere in-
frequently reported.Onepatient in themonotherapy armand
2 patients in the combination arm had acute hepatitis with-
out hepatic failure, and 1 patient in the combination arm had
renal failureattributedtoacute interstitialnephritisandneeded
Table 2. Primary and Secondary End Pointsa
End Point
Monotherapy
(n = 291)
Combination Therapy
(n = 289) P Value
Primary end point
Patients not reaching clinical stability at day 7b 120 (41.2) 97 (33.6) .07
Secondary end points
Intensive care unit admission 12 (4.1) 14 (4.8) .68
Complicated pleural effusionc 8 (2.7) 14 (4.8) .19
Length of stay, median (IQR), d 8 (6-13) 8 (6-12) .65
Any change in the initial antibiotic treatment 39 (13.4) 46 (15.8) .39
In-hospital death 8 (2.7) 7 (2.4) .80
30-Day death 14 (4.8) 10 (3.4) .42
90-Day death 24 (8.2) 20 (6.9) .54
30-Day readmission 23 (7.9) 9 (3.1) .01
90-Day readmission 47 (16.2) 37 (12.7) .25
New pneumonia within 30 daysd 10 (3.4) 6 (2.1) .31
Abbreviation: IQR, interquartile
range.
a Data are presented as number
(percentage) of patients unless
otherwise indicated.
bBetween-arm difference was 7.6%
(1-sided 90%CI, 13.0%; 2-sided
95% CI, −0.8% to 16.0%).
c Need for thoracic drainage or
surgery.
d Pneumonia confirmed by
radiography and need for a new
antibiotic treatment.
Table 3. Hazard Ratios for Clinical Stability in theMonotherapy Arm vs Combination Arm
Variable No. of Patients Hazard Ratioa (95% CI) P Value
Unadjusted 0.93 (0.76-1.13) .46
Adjusted for age and PSI category 0.92 (0.76-1.12) .41
Stratified
Atypical 31 0.33 (0.13-0.85) .02
Nonatypical 549 0.99 (0.80-1.22) .93
P value for interaction .03
PSI category IV 240 0.81 (0.59-1.10) .18
PSI category I-III 340 1.06 (0.82-1.36) .66
P value for interaction .18
CURB-65 category 2-5 311 0.80 (0.61-1.06) .12
CURB-65 category 0-1 269 1.13 (0.85-1.50) .40
P value for interaction .09
Age, y
<65 150 1.09 (0.75-1.59) .65
≥65 430 0.87 (0.70-1.10) .25
P value for interaction .32
Abbreviations: CURB-65, confusion,
urea, respiratory rate, blood pressure,
age of 65 years or older;
PSI, Pneumonia Severity Index.
a Reference category is the
combination arm.
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hemodialysis. Minor allergic reactions were reported in 3 pa-
tients in each arm.
Discussion
Wewereunable todemonstratenoninferiorityof initial empiri-
cal treatment with a β-lactam agent alone in hospitalized pa-
tients with moderately severe community-acquired pneumo-
nia. There was a nonsignificant trend toward superiority of
combination therapy, which could represent a chance finding
or true superiority that was not significant because of insuffi-
cient power. Although most secondary outcomes did not dif-
fer between the 2 treatment arms, patients in the mono-
therapyarmhadmorereadmissionswithin30days.This finding
might also point toward a superiority of combination therapy.
One advantage of the combination therapy is added cov-
erage of atypical pathogens with the macrolide. A Cochrane
review5 included randomized clinical trials that compared
treatment regimens with andwithout atypical coverage. The
reviewdidnot findadifference inmortality (relative risk [RR],
1.14; 95% CI, 0.84-1.55), but there was a nonsignificant trend
toward fewerclinical failures in theatypical arm(RR,0.93;95%
CI,0.84-1.04).However,macrolide treatmentmight alsoaffect
favorably thehost inflammatory response throughnonantibi-
otic effects.14,20Macrolide treatment confers clinical benefits
in chronic inflammatory airway conditions, such as
bronchiectasis21 andchronicobstructivepulmonarydisease,22
but thisbenefit isnotestablished incommunity-acquiredpneu-
monia. In a recentmeta-analysis,23macrolide usewas associ-
ated with a statistically significant mortality reduction (RR,
0.78; 95%CI, 0.64-0.95), an advantage that disappearedwhen
the analysis was restricted to randomized clinical trials (RR,
1.13; 95% CI, 0.65-1.98). A meta-analysis2 of 16 observational
studies comparing β-lactam–macrolide combination with a
single β-lactam in more than 42000 patients with all-cause
pneumonia found a lower risk of death in favor of the combi-
nation treatment (odds ratio, 0.67; 95% CI, 0.61-0.73). An ad-
vantage for combination therapyalsohasbeen reported forpa-
tientswithSpneumoniae, althoughthispathogen isadequately
coveredbyβ-lactamdrugs.24,25 This advantage, not present in
all studies,26-28 fueled the hypothesis of an immunomodula-
tory effect of the macrolide.
In our study, combination therapy was superior in pa-
tients with proven infection by an atypical pathogen, despite
systematic search for L pneumophila infection by urinary anti-
gen testing and subsequent addition of amacrolide in patients
undergoingmonotherapy.Thissuperioritymaybeexplainedby
failure to provide timely coverage of the Legionella infection.
Themedian timebetweenadministrationof theβ-lactamdrug
andtheadditionofclarithromycinwas47hoursforpatientswith
Lpneumophila infection in themonotherapyarm.This long in-
terval reflects real-lifepractice,withdelays incollectingaurine
sample for testing, receiving the results, andprescribing theap-
propriate antibiotic. Thesedelaysmayhavehad repercussions
on the concerned patients because 3 of themwere transferred
totheintensivecareunitbecauseofclinicaldeterioration(eTable
5 intheSupplement).Moreover,sensitivityof thetest forLpneu-
mophila serotype 1 is only approximately 80%, andother sero-
types or species of Legionella are inconsistently detected. Fi-
nally, the health care professionals were not informed of the
result of the swab test forMpneumoniaeandCpneumoniaede-
tection, and lackof initial coverage for thesebacteria couldalso
explain the observed difference.
Although clear, this superiority in patients with atypical
pathogens does not completely explain the difference in out-
comes in the combination arm. First, there was a clear trend
towardsuperiorityof thecombinationtherapyforpatientswith
more severe pneumonia (PSI category IV or CURB-65 score of
≥2).This finding is inaccordancewithobservational studies25,29
that foundthathigher survivalwithcombination therapycom-
paredwithmonotherapywas restricted topatientswithmore
severe pneumonia. Because PSI scores did not differ signifi-
cantlybetweenpatientswithandwithout infectionwithatypi-
cal pathogens, better coverage of atypical pathogens is un-
likely to explain this differential effect. Second, in an analysis
that excluded patients with atypical pathogens, the ten-
dency toward a better outcome in the combination arm per-
sisted (proportion of patients not attaining clinical stability 7
days after treatment, 5.8% compared with 7.6% in the pri-
mary analysis). Third, noneof the 23patients readmitted at 30
days in the monotherapy arm had been infected by an atypi-
cal pathogen. Better control of the host inflammatory re-
sponse throughanonantibiotic effect of clarithromycinmight
have protectedpatients in the combination arm fromadverse
events that led to readmission.
Patients enrolled in the trial are representative of pa-
tients commonlyhospitalized for community-acquiredpneu-
monia, with 25% of patients older than 84 years and a high
prevalence of chronic disease. We used strict inclusion crite-
ria. Less than 5% of patients had been treated with oral anti-
biotics before inclusion, maximizing the effect of the allo-
cated therapy, and adherence to the protocol and follow-up
were excellent,with only 3 patients unavailable for follow-up
and85 (14.7%)with a change in treatment allocation (Figure 1
Figure 2. Proportions of Patients Not Reaching Clinical Stability
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and Table 2). The primary outcome was based on objective
physiological measurements, and outcome assessment was
masked. Finally, we assessed the outcome at an early time
point, in accordance with published recommendations.30,31
Our trial was open, and knowledge of treatment arm allo-
cationcouldhavebiasedclinicaldecisionmaking.However,we
did not observe a difference in the adherence to the assigned
treatmentbetweenthe2arms.ThestudywasconductedinSwit-
zerland,andresultscannotautomaticallybegeneralizedtoother
regionswhereprevalenceof atypical bacteria and resistanceof
Spneumoniaemaydiffer.Specifically,Lpneumophilacauses93%
to98%ofLegionellapneumonias in Switzerland,most of them
being diagnosed by urinary antigen testing.32
Ahighpercentageof patients hadnot reached clinical sta-
bility at 7 days, and the median time to clinical stability was
higher than inother trials.33,34However, our resultswere com-
parable with those of a large international observational
study.35Several characteristicsofourstudycanexplain the lon-
ger-than-expected time to clinical stability. We took into ac-
count patients dying in the hospital and patients who never
reached clinical stability during the acute care stay but were
later transferred to a rehabilitation facility by censoring them
at30days.Thesepatientswereexcludedfromotherstudies33,34
that evaluated time to clinical stability. In fact, when we re-
peated the analysis on the population of patients discharged
to their home, we found amedian time to clinical stability of
3.5 days (IQR, 3.1-3.9 days), in line with previous studies.33,34
Finally,despite randomization, a striking imbalancewas found
in the repartition of Legionella between the treatment arms,
which could have favored the combination arm.
Conclusions
Our results have important clinical implications. First, the re-
sults of this trial indicate that initial empirical treatmentwith
β-lactammonotherapydelays clinical stability for patients in-
fectedwith atypical pathogens, evenwhen thepresenceofLe-
gionella is systematically searchedforwithurinaryantigentest-
ing.Whether faster introductionofamacrolide inpatientswith
a positive test result would have resulted in better outcomes
ishypothetical. Second,patientswithhigher severityofpneu-
monia (PSI category IV or CURB-65 score of ≥2) seem also to
benefit from combination therapy. Future work might test a
strategy of tailoring the initial therapy on the severity of the
pneumonia, with combination therapy reserved for patients
with PSI category IV or higher pneumonia or a CURB-65 score
of 2 or greater.
ARTICLE INFORMATION
Accepted for Publication: July 4, 2014.
Published Online:October 6, 2014.
doi:10.1001/jamainternmed.2014.4887.
Author Affiliations:Division of General Internal
Medicine, Geneva University Hospitals and Faculty
of Medicine, Geneva, Switzerland (Garin, Carballo,
Nendaz, Perrier); Division of Internal Medicine,
Hôpital Riviera-Chablais, Monthey, Switzerland
(Garin); Division of Internal Medicine, Hôpital
Neuchâtelois–La Chaux-de-Fonds, La Chaux-de-
Fonds, Switzerland (Genné, Seravalli); Division of
Internal Medicine, Hôpital Cantonal, Fribourg,
Switzerland (Chuard); Division of Internal Medicine,
Triemlispital, Zurich, Switzerland (Eich); Emergency
Department, Centre Hospitalier Universitaire
Vaudois, Lausanne, Switzerland (Hugli); Division of
Internal Medicine, Centre Hospitalier Universitaire
Vaudois, Lausanne, Switzerland (Lamy); Division of
Internal Medicine, Hôpital du Valais, Sion,
Switzerland (Petignat); Division of Clinical
Epidemiology, Geneva University Hospitals and
Faculty of Medicine, Geneva, Switzerland
(Perneger); Emergency Department, Geneva
University Hospitals and Faculty of Medicine,
Geneva, Switzerland (Rutschmann); Division of
Infectious Diseases, Geneva University Hospitals
and Faculty of Medicine, Geneva, Switzerland
(Harbarth).
Author Contributions:Dr Garin had full access to
all the data in the study and takes responsibility for
the integrity of the data and the accuracy of the
data analysis.
Study concept and design: Garin, Genné, Nendaz,
Perneger, Rutschmann, Harbarth, Perrier.
Acquisition, analysis, or interpretation of data:
Garin, Carballo, Chuard, Eich, Hugli, Lamy, Nendaz,
Petignat, Perneger, Rutschmann, Seravalli,
Harbarth, Perrier.
Drafting of the manuscript: Garin, Hugli, Petignat.
Critical revision of the manuscript for important
intellectual content: Garin, Genné, Carballo, Chuard,
Eich, Hugli, Lamy, Nendaz, Perneger, Rutschmann,
Seravalli, Harbarth, Perrier.
Statistical analysis: Garin, Hugli, Perneger,
Harbarth, Perrier.
Obtained funding: Garin.
Administrative, technical, or material support: Garin,
Genné, Carballo, Hugli, Lamy, Nendaz, Petignat,
Seravalli.
Study supervision: Garin, Genné, Carballo, Lamy,
Rutschmann, Seravalli.
Conflict of Interest Disclosures:None reported.
Funding/Support: The study was supported by
grant 3200BO-120074 from the Swiss National
Science Foundation (Dr Perrier) and grants from the
Clinical Trial Unit and the Department of Internal
Medicine of Geneva University Hospitals (Dr Garin).
Role of the Funder/Sponsor: The funding sources
had no role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and the decision to
submit themanuscript for publication.
Additional Contributions:Michelle Le Braz served
as the data manager of the trial. We are indebted to
all the physicians and nurses who provided study
patients: Maryam Ackermann-Zare, MD, Christiane
Anex, Gregory Berra, MD, Valentina Bischof,
Caroline Brossier, Florence Dartiguenave, Magali
Dornier, Yves Flattet, MD, Ute Hornberger, Sophie
Levannier, Vincent Poffet, MD, Nora Schwotzer,
MD, and Alexis Zawodnik, MD, MPH. Mss Anex,
Bischof, Brossier, Dartiguenave, Dornier,
Hornberger, and Levannier were employed for the
trial and received financial compensation.
REFERENCES
1. Welte T, Torres A, Nathwani D. Clinical and
economic burden of community-acquired
pneumonia among adults in Europe. Thorax. 2012;
67(1):71-79.
2. NieW, Li B, Xiu Q. β-Lactam/macrolide dual
therapy versus β-lactammonotherapy for the
treatment of community-acquired pneumonia in
adults: a systematic review andmeta-analysis.
J Antimicrob Chemother. 2014;69(6):1441-1446.
3. Paul M, Nielsen AD, Gafter-Gvili A, et al. The
need for macrolides in hospitalised
community-acquired pneumonia: propensity
analysis. Eur Respir J. 2007;30(3):525-531.
4. Rodrigo C, McKeever TM,WoodheadM, LimWS.
Single versus combination antibiotic therapy in
adults hospitalised with community acquired
pneumonia. Thorax. 2012;68(5):493-495.
5. Eliakim-Raz N, Robenshtok E, Shefet D, et al.
Empiric antibiotic coverage of atypical pathogens
for community-acquired pneumonia in hospitalized
adults. Cochrane Database Syst Rev. 2012;9:
CD004418.
6. Mandell LA, Wunderink RG, Anzueto A, et al;
Infectious Diseases Society of America; American
Thoracic Society. Infectious Diseases Society of
America/American Thoracic Society consensus
guidelines on themanagement of
community-acquired pneumonia in adults. Clin
Infect Dis. 2007;44(suppl 2):S27-S72.
7. WoodheadM, Blasi F, Ewig S, et al; Joint
Taskforce of the European Respiratory Society and
European Society for Clinical Microbiology and
Infectious Diseases. Guidelines for the
management of adult lower respiratory tract
infections—full version. Clin Microbiol Infect. 2011;17
(suppl 6):1-59.
8. Schembri S, Williamson PA, Short PM, et al.
Cardiovascular events after clarithromycin use in
lower respiratory tract infections: analysis of two
prospective cohort studies. BMJ. 2013;346:f1235.
doi:10.1136/bmj.f1235.
9. RayWA, Murray KT, Hall K, Arbogast PG, Stein
CM. Azithromycin and the risk of cardiovascular
death.N Engl J Med. 2012;366(20):1881-1890.
Research Original Investigation β-Lactam Treatment for Pneumonia
1900 JAMA Internal Medicine December 2014 Volume 174, Number 12 jamainternalmedicine.com
Downloaded From:  by a UNIVERSITE DE LAUSANNE User  on 10/13/2017
Copyright 2014 American Medical Association. All rights reserved.
10. Mortensen EM, Halm EA, PughMJ, et al.
Association of azithromycin with mortality and
cardiovascular events among older patients
hospitalized with pneumonia. JAMA. 2014;311(21):
2199-2208.
11. Corrales-Medina VF, Musher DM,Wells GA,
Chirinos JA, Chen L, Fine MJ. Cardiac complications
in patients with community-acquired pneumonia:
incidence, timing, risk factors, and association with
short-termmortality.Circulation. 2012;125(6):773-781.
12. Vanderkooi OG, Low DE, Green K, Powis JE,
McGeer A; Toronto Invasive Bacterial Disease
Network. Predicting antimicrobial resistance in
invasive pneumococcal infections. Clin Infect Dis.
2005;40(9):1288-1297.
13. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E,
Vardy D, Dagan R. Community prescribing and
resistant Streptococcus pneumoniae. Emerg Infect
Dis. 2005;11(6):829-837.
14. Kanoh S, Rubin BK. Mechanisms of action and
clinical application of macrolides as
immunomodulatory medications. Clin Microbiol Rev.
2010;23(3):590-615.
15. Fine MJ, Auble TE, Yealy DM, et al. A prediction
rule to identify low-risk patients with
community-acquired pneumonia.N Engl J Med.
1997;336(4):243-250.
16. D’Agostino RB Sr, Massaro JM, Sullivan LM.
Non-inferiority trials: design concepts and issues:
the encounters of academic consultants in
statistics. Stat Med. 2003;22(2):169-186.
17. Genné D, Kaiser L, Kinge TN, Lew D.
Community-acquired pneumonia: causes of
treatment failure in patients enrolled in clinical
trials. Clin Microbiol Infect. 2003;9(9):949-954.
18. Halm EA, Fine MJ, Marrie TJ, et al. Time to
clinical stability in patients hospitalized with
community-acquired pneumonia: implications for
practice guidelines. JAMA. 1998;279(18):1452-1457.
19. Machin D, Campbell MJ, Fayers PM, Pinol A.
Sample Size Tables for Clinical Studies. 2nd ed.
Oxford, England: Blackwell Science; 1997.
20. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki
E, Maltezos E, Zarogoulidis K. Macrolides: from in
vitro anti-inflammatory and immunomodulatory
properties to clinical practice in respiratory
diseases. Eur J Clin Pharmacol. 2012;68(5):479-503.
21. Serisier DJ, Martin ML, McGuckin MA, et al.
Effect of long-term, low-dose erythromycin on
pulmonary exacerbations among patients with
non-cystic fibrosis bronchiectasis: the BLESS
randomized controlled trial. JAMA. 2013;309(12):
1260-1267.
22. Albert RK, Connett J, BaileyWC, et al; COPD
Clinical Research Network. Azithromycin for
prevention of exacerbations of COPD.N Engl J Med.
2011;365(8):689-698.
23. Asadi L, Sligl WI, Eurich DT, et al.
Macrolide-based regimens andmortality in
hospitalized patients with community-acquired
pneumonia: a systematic review andmeta-analysis.
Clin Infect Dis. 2012;55(3):371-380.
24. Martínez JA, Horcajada JP, Almela M, et al.
Addition of a macrolide to a β-lactam-based
empirical antibiotic regimen is associated with
lower in-hospital mortality for patients with
bacteremic pneumococcal pneumonia.Clin Infect Dis.
2003;36(4):389-395.
25. Baddour LM, Yu VL, Klugman KP, et al;
International Pneumococcal Study Group.
Combination antibiotic therapy lowers mortality
among severely ill patients with pneumococcal
bacteremia. Am J Respir Crit Care Med. 2004;170
(4):440-444.
26. Harbarth S, Garbino J, Pugin J, Romand JA,
Pittet D. Lack of effect of combination antibiotic
therapy onmortality in patients with pneumococcal
sepsis. Eur J Clin Microbiol Infect Dis. 2005;24(10):
688-690.
27. Dwyer R, Ortqvist A, Aufwerber E, et al.
Addition of a macrolide to a ss-lactam in bacteremic
pneumococcal pneumonia. Eur J Clin Microbiol
Infect Dis. 2006;25(8):518-521.
28. Burgess DS, Lewis JS II. Effect of macrolides as
part of initial empiric therapy onmedical outcomes
for hospitalized patients with community-acquired
pneumonia. Clin Ther. 2000;22(7):872-878.
29. Rodríguez A, Mendia A, Sirvent JM, et al;
CAPUCI Study Group. Combination antibiotic
therapy improves survival in patients with
community-acquired pneumonia and shock. Crit
Care Med. 2007;35(6):1493-1498.
30. Talbot GH, Powers JH, Fleming TR, Siuciak JA,
Bradley J, Boucher H; CABP-ABSSSI Project Team.
Progress on developing endpoints for registrational
clinical trials of community-acquired bacterial
pneumonia and acute bacterial skin and skin
structure infections: update from the Biomarkers
Consortium of the Foundation for the National
Institutes of Health. Clin Infect Dis. 2012;55(8):1114-
1121.
31. File TM Jr, Marrie TJ. Does empiric therapy for
atypical pathogens improve outcomes for patients
with CAP? Infect Dis Clin North Am. 2013;27(1):99-114.
32. Office Fédéral de la Santé Publique. La
Légionellose en Suisse: Cas Recensés de 2004 à
2008. Berne, Switzerland: Office Fédéral de la
Santé Publique, Unité de Direction Santé Publique,
DivisionMaladies Transmissibles; 2008:651-655.
33. Menéndez R, Torres A, Rodríguez de Castro F,
et al; Neumofail Group. Reaching stability in
community-acquired pneumonia: the effects of the
severity of disease, treatment, and the
characteristics of patients. Clin Infect Dis. 2004;39
(12):1783-1790.
34. Silber SH, Garrett C, Singh R, et al. Early
administration of antibiotics does not shorten time
to clinical stability in patients with
moderate-to-severe community-acquired
pneumonia. Chest. 2003;124(5):1798-1804.
35. Arnold FW, Summersgill JT, Lajoie AS, et al;
Community-Acquired Pneumonia Organization
(CAPO) Investigators. A worldwide perspective of
atypical pathogens in community-acquired
pneumonia. Am J Respir Crit Care Med. 2007;175
(10):1086-1093.
Invited Commentary
The Debate on Antibiotic Therapy for Patients Hospitalized
for Pneumonia
Where ShouldWe Go FromHere?
Jonathan S. Lee, MD; Michael J. Fine, MD, MSc
Although our understanding of pneumonia dates back thou-
sands of years to when symptoms were recognized by Hip-
pocrates, the first typical bacterial pathogen responsible for
causing community-acquired pneumonia (CAP), Streptococ-
cus pneumoniae,was not iso-
lated until the late 19th cen-
tury. Another half a century
passedbefore 3 atypical bacteriawerediscovered as pneumo-
nia pathogens (ie, Mycoplasma pneumoniae in 1944, Legion-
ella species in 1976, andChlamydiapneumoniae in 1981).Mean-
while, treatment for CAP only became available in the 1940s
with the advent of penicillin followed by cephalosporins. Al-
though macrolides were discovered in the 1950s, newer-
generationdrugs in this classnowcommonlyused to treatCAP
(eg, azithromycin and clarithromycin) were approved by the
FoodandDrugAdministration in theearly 1990s. Similarly, al-
though discovered in the 1960s, advanced-generation respi-
ratory fluoroquinolones (eg, levofloxacin, moxifloxacin, and
gemifloxacin) were approved between 1996 and 2003.
Contemporary research has added important clinical
precepts for the etiology, diagnosis, and clinical presentation
of CAP that further inform the antibiotic treatment debate.
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